319 related articles for article (PubMed ID: 27713122)
1. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
2. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Ozaki T; Yu M; Yin D; Sun D; Zhu Y; Bu Y; Sang M
BMC Cancer; 2018 Mar; 18(1):309. PubMed ID: 29558908
[TBL] [Abstract][Full Text] [Related]
3. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death.
Nakamura M; Sugimoto H; Ogata T; Hiraoka K; Yoda H; Sang M; Sang M; Zhu Y; Yu M; Shimozato O; Ozaki T
Oncogenesis; 2016 Jun; 5(6):e233. PubMed ID: 27294865
[TBL] [Abstract][Full Text] [Related]
4. Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres.
Sang M; Nakamura M; Ogata T; Sun D; Shimozato O; Nikaido T; Ozaki T
Oncol Rep; 2018 Jun; 39(6):2749-2758. PubMed ID: 29620279
[TBL] [Abstract][Full Text] [Related]
5. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H; Nakamura M; Yoda H; Hiraoka K; Shinohara K; Sang M; Fujiwara K; Shimozato O; Nagase H; Ozaki T
Cell Death Discov; 2015; 1():15010. PubMed ID: 27551445
[TBL] [Abstract][Full Text] [Related]
6. Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.
Ogata T; Nakamura M; Sang M; Yoda H; Hiraoka K; Yin D; Sang M; Shimozato O; Ozaki T
PLoS One; 2017; 12(7):e0179884. PubMed ID: 28671946
[TBL] [Abstract][Full Text] [Related]
7. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H; Nakamura M; Yoda H; Hiraoka K; Shinohara K; Sang M; Fujiwara K; Shimozato O; Nagase H; Ozaki T
Cell Death Dis; 2015 Oct; 6(10):e1914. PubMed ID: 26469963
[No Abstract] [Full Text] [Related]
8. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
[TBL] [Abstract][Full Text] [Related]
9. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
10. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
11. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Liu ZJ; Xu W; Han J; Liu QY; Gao LF; Wang XH; Li XL
Anticancer Drugs; 2020 Aug; 31(7):684-692. PubMed ID: 32282368
[TBL] [Abstract][Full Text] [Related]
12. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
13. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
Wu P; Wang X; Ma Y; Xu X; Liu W; Sheng Z; Chen M; Zhou R; Zhang K; Goodin S; Zheng X; Li D
Bioorg Chem; 2020 Aug; 101():104022. PubMed ID: 32599367
[TBL] [Abstract][Full Text] [Related]
14. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
15. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
16. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
17. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
18. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
[TBL] [Abstract][Full Text] [Related]
19. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
[TBL] [Abstract][Full Text] [Related]
20. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
